Key Insights: Direct Fund IV exhibits strong early returns, boosted by successful exits such as Medispec. Conversely, Direct Fund I, now fully realized, did not meet its 12% target. Direct Fund III is navigating a recovery from recent challenges, while Direct Fund II has stabilized after its peak performance. The mixed performance of Outsourced Tranche I and the current underperformance of Outsourced Tranche II underscore the distinct advantages of Ekuinas's direct investment and control model.